BACKGROUND Yigong San(YGS)is a representative prescription for the treatment of digestive disorders,which has been used in clinic for more than 1000 years.However,the mechanism of its anti-gastric cancer and regulate ...BACKGROUND Yigong San(YGS)is a representative prescription for the treatment of digestive disorders,which has been used in clinic for more than 1000 years.However,the mechanism of its anti-gastric cancer and regulate immunity are still remains unclear.AIM To explore the mechanism of YGS anti-gastric cancer and immune regulation.METHODS Firstly,collect the active ingredients and targets of YGS,and the differentially expressed genes of gastric cancer.Secondly,constructed a protein-protein interaction network between the targets of drugs and diseases,and screened hub genes.Then the clinical relevance,mutation and repair,tumor microenvironment and drug sensitivity of the hub gene were analyzed.Finally,molecular docking was used to verify the binding ability of YGS active ingredient and hub genes.RESULTS Firstly,obtained 55 common targets of gastric cancer and YGS.The Kyoto Encyclopedia of Genes and Genomes screened the microtubule-associated protein kinase signaling axis as the key pathway and IL6,EGFR,MMP2,MMP9 and TGFB1 as the hub genes.The 5 hub genes were involved in gastric carcinogenesis,staging,typing and prognosis,and their mutations promote gastric cancer progression.Finally,molecular docking results confirmed that the components of YGS can effectively bind to therapeutic targets.CONCLUSION YGS has the effect of anti-gastric cancer and immune regulation.展开更多
目的 探讨异功散加味联合重组人生长激素(recombinant human growth hormone,rhGH)对脾肾虚弱型特发性矮小症(idiopathic short stature,ISS)患儿生长发育及血清胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)水平的影响。方...目的 探讨异功散加味联合重组人生长激素(recombinant human growth hormone,rhGH)对脾肾虚弱型特发性矮小症(idiopathic short stature,ISS)患儿生长发育及血清胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)水平的影响。方法 选取2020年6月至2021年6月于温州市中心医院就诊的脾肾虚弱型ISS患儿80例,根据随机数字表法将其分为对照组和治疗组,每组各40例。对照组患儿给予rhGH注射液治疗;治疗组患儿在对照组治疗的基础上联合异功散加味治疗。两组患儿连续治疗12个月。比较两组患儿的生长发育情况、脾肾虚弱证单项症状评分、临床疗效、血清IGF-1水平和不良反应发生率。结果 干预12个月后,两组患儿的身高、骨龄、血清IGF-1水平均显著高于本组治疗前,脾肾虚弱证单项症状评分均显著低于本组治疗前(P<0.05);治疗组患儿的身高、骨龄、血清IGF-1水平均显著高于对照组,脾肾虚弱证单项症状评分均显著低于对照组(P<0.05)。治疗组患儿的总有效率显著高于对照组(χ^(2)=4.132,P=0.042)。治疗组患儿的不良反应发生率显著低于对照组(χ^(2)=5.400,P=0.020)。结论 异功散加味联合rhGH治疗脾肾虚弱型ISS患儿的疗效较好,有利于促进患儿生长发育,改善中医证候评分,上调血清IGF-1水平,且安全性良好。展开更多
目的通过对慢性病贫血(anemia of chronic disease,ACD)患者血清中铁调节激素(Hep)、血红蛋白(Hb)、白介素-6(IL-6)、白介素-10(IL-10)水平变化的分析,评价异功散加减联合重组人促红细胞生成素(rhEPO)治疗ACD的疗效。方法将本院收治的80...目的通过对慢性病贫血(anemia of chronic disease,ACD)患者血清中铁调节激素(Hep)、血红蛋白(Hb)、白介素-6(IL-6)、白介素-10(IL-10)水平变化的分析,评价异功散加减联合重组人促红细胞生成素(rhEPO)治疗ACD的疗效。方法将本院收治的80例ACD患者随机分为4组,每组20例。对照组仅治疗基础病,如化疗、抗感染等,不针对贫血治疗;rhEPO组给予rhEPO 150U/kg,皮下注射,隔日1次;异功散组予以异功散加减,每日1剂,早晚分服;异功散联合rhEPO组(联合组)予以异功散加减,每日1剂,早晚分服,rhEPO 150U/kg,皮下注射,隔日1次。分别于治疗前及治疗后1个月,检测各组血清中Hep、Hb、IL-6、IL-10的水平。结果与对照组比较,异功散组、rhEPO组及联合组治疗后Hb水平明显升高,而血清Hep、IL-6、IL-10水平均下降,差异均有统计学意义(P<0.05);联合组较异功散组及rhEPO组治疗后Hb升高更明显,且血清Hep、IL-6、IL-10下降更显著,差异均有统计学意义(P<0.05)。结论异功散加减可提高ACD患者Hb水平,并降低Hep、IL-6及IL-10水平,可用于ACD的治疗。异功散加减联合rhEPO治疗ACD的疗效明显优于二者的单独使用。展开更多
基金Supported by Ningxia Key Research and Development Program,No.2023BEG02015Ningxia Science and Technology Benefiting People Program,No.2022CMG03064+1 种基金Ningxia Natural Science Foundation,No.2022AAC02039National Natural Science Foundation of China,No.82260879 and No.82374261.
文摘BACKGROUND Yigong San(YGS)is a representative prescription for the treatment of digestive disorders,which has been used in clinic for more than 1000 years.However,the mechanism of its anti-gastric cancer and regulate immunity are still remains unclear.AIM To explore the mechanism of YGS anti-gastric cancer and immune regulation.METHODS Firstly,collect the active ingredients and targets of YGS,and the differentially expressed genes of gastric cancer.Secondly,constructed a protein-protein interaction network between the targets of drugs and diseases,and screened hub genes.Then the clinical relevance,mutation and repair,tumor microenvironment and drug sensitivity of the hub gene were analyzed.Finally,molecular docking was used to verify the binding ability of YGS active ingredient and hub genes.RESULTS Firstly,obtained 55 common targets of gastric cancer and YGS.The Kyoto Encyclopedia of Genes and Genomes screened the microtubule-associated protein kinase signaling axis as the key pathway and IL6,EGFR,MMP2,MMP9 and TGFB1 as the hub genes.The 5 hub genes were involved in gastric carcinogenesis,staging,typing and prognosis,and their mutations promote gastric cancer progression.Finally,molecular docking results confirmed that the components of YGS can effectively bind to therapeutic targets.CONCLUSION YGS has the effect of anti-gastric cancer and immune regulation.